Biotech Values

[exwannabe]

GTOP MyVax P3 trial data soon.

The last patient follow-up fr the trial of MyVax in follicular NHL is in November, the company says top line results by EOY.

The stock price took a big hit over a year ago when it missed having an interum reach the P value goal. Then Aschroft (who had been a big backer) went negative.

My assumption would be that there must still be a decent chance to hit stat-sig else the trial would have been stopped for futility by the DSMB last year. As such, it seams like a decent gamble (obviously not a shure thing, as if so the interrum would have hot it's goal).

Is there anything in this makes this any worse than my view?